Get the Stockscreener App
0.00
9,900%
0.0005
Vaxxinity Inc stock is traded at $0.00, with a volume of 0.
It is up +9,900% in the last 24 hours and down -87.90% over the past month.
See More
Previous Close:
$0.0005
Open:
$0
24h Volume:
0
Relative Volume:
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-66.00M
P/E Ratio:
0.00
EPS:
-0.53
Net Cash Flow:
$-60.55M
1W Performance:
+9,900%
1M Performance:
-87.90%
6M Performance:
-95.00%
1Y Performance:
-97.29%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.00
Vaxxinity Inc Stock (VAXX) Company Profile
Compare VAXX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VAXX
Vaxxinity Inc
|
0.00 | 0 | 0 | -66.00M | -60.55M | -0.53 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Vaxxinity Inc Stock (VAXX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-08-23 | Initiated | Robert W. Baird | Outperform |
| Apr-27-22 | Initiated | Evercore ISI | In-line |
Vaxxinity Inc Stock (VAXX) Latest News
Head to Head Contrast: ANI Pharmaceuticals (NASDAQ:ANIP) vs. Vaxxinity (NASDAQ:VAXX) - Defense World
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - MSN
Comparing Dynavax Technologies (NASDAQ:DVAX) & Vaxxinity (NASDAQ:VAXX) - Defense World
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity - The Pharma Letter
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial - Nature
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - InvestorPlace
Vaxxinity Issues Shareholder Letter - GlobeNewswire
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - GlobeNewswire
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
Vaxxinity Announces Positive Target Engagement Data from - GlobeNewswire
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - GlobeNewswire
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewswire
Vaxxinity, University of Florida join for work on Parkinson’s vaccine - Parkinson's News Today
Vaxxinity, UF Join Forces Against Neurodegenerative Diseases - Yahoo Finance
Could space travel research deliver a frailty vaccine? - Longevity.Technology
Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space - Fierce Biotech
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Mei Mei Hu - The World Economic Forum
Private companies invested in Vaxxinity, Inc. (NASDAQ:VAXX) copped the brunt of last week's US$41m market cap decline - Yahoo Finance
Baird Starts Vaxxinity With Outperform Rating, Price Target is $7 - MarketScreener
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX) - Yahoo Finance
Fast-Tracked Alzheimer’s Vaccine Seems to Work, But Phase 3 Trials Stalled - Being Patient
Vaxxinity Alzheimer’s treatment shows promising results in early trial - BioPharma-Reporter.com
Innovative Alzheimer's Disease Vaccine Candidate Can Add Value - Vax-Before-Travel
Vaxxinity Appoints Dr. Peter Powchik as Global Scientific Director - Yahoo Finance
Vaxxinity Appoints Peter Powchik, M.D., to EVP, Global Scientific Director - citybiz
Promising Milestone in Neurodegenerative Disease Treatment: Vaxxinity’s UB-312 in Parkinson’s Patients - Yahoo 財經
Michael J. Fox Foundation Funds Parkinson’s Disease Vaccine Candidate - Vax-Before-Travel
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease - southfloridahospitalnews.com
Vaxxinity celebrates trial success in early Parkinson’s therapy - Clinical Trials Arena
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson’s Disease - GlobeNewswire
Vaxxinity Reports First Quarter 2023 Financial Results and Provides Corporate Update - GlobeNewswire
Weekly Biotech Pulse: Vaxxinity results, Biogen's FDA review, and more | Pro Recap - Investing.com India
VXX-301, a tau vaccine with optimized properties - BioWorld MedTech
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April - Yahoo News Canada
Vaxxinity Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Updates - GlobeNewswire
Clinical Trial of Investigational Vaccine to Treat LDL Cholesterol Underway - Diagnostic and Interventional Cardiology
Vaxxinity Announces First Subjects Dosed in Phase 1 - GlobeNewswire
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences - GlobeNewswire
Vaxxinity Announces Board Appointments - citybiz
Why Shares of Vaxxinity Jumped This Week - The Motley Fool
Vaxxinity Stock: Potential Strong Upsides Ahead (NASDAQ:VAXX) - Seeking Alpha
Robinhood Gave Its Customers Access to IPOs That All Flopped - Bloomberg
Multiple insiders bought Vaxxinity, Inc. (NASDAQ:VAXX) stock earlier this year, a positive sign for shareholders - Yahoo Finance
Vaxxinity vaccine to treat Alzheimer’s wins FDA fast-track designation - Dallas News
Vaxxinity Inc Stock (VAXX) Financials Data
Revenue
Net Income
Cash Flow
EPS
17.27%
1.06%
Cap:
|
Volume (24h):